Ivor Elrifi Buys 83,807 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi bought 83,807 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were bought at an average price of $0.97 per share, for a total transaction of $81,292.79. Following the acquisition, the chief executive officer directly owned 4,556,068 shares of the company’s stock, valued at $4,419,385.96. This represents a 1.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ivor Elrifi also recently made the following trade(s):

• On Wednesday, August 5th, Ivor Elrifi purchased 237,616 shares of Tiziana Life Sciences stock. The stock was bought at an average price of $1.00 per share, with a total value of $237,616.00.
• On Monday, August 3rd, Ivor Elrifi purchased 667,000 shares of Tiziana Life Sciences stock. The shares were bought at an average cost of $1.00 per share, for a total transaction of $667,000.00.

Tiziana Life Sciences Trading Up 2.6%

Shares of Tiziana Life Sciences stock opened at $1.00 on Friday. Tiziana Life Sciences Ltd has a 12-month low of $0.87 and a 12-month high of $2.53. The business’s 50 day moving average is $1.13 and its 200-day moving average is $1.30.

Institutional Investors Weigh In On Tiziana Life Sciences

A number of institutional investors have recently made changes to their positions in the company. Zhang Financial LLC increased its position in Tiziana Life Sciences by 12.0% during the 1st quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock worth $131,000 after buying an additional 12,000 shares during the period. Marshall Wace LLP boosted its position in shares of Tiziana Life Sciences by 5.2% in the fourth quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock valued at $420,000 after acquiring an additional 14,005 shares during the period. Rachor Investment Advisory Services LLC bought a new stake in shares of Tiziana Life Sciences in the fourth quarter valued at about $25,000. Cubist Systematic Strategies LLC acquired a new position in shares of Tiziana Life Sciences in the first quarter valued at about $25,000. Finally, HRT Financial LP acquired a new position in shares of Tiziana Life Sciences in the fourth quarter valued at about $36,000.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on TLSA shares. Zacks Research upgraded shares of Tiziana Life Sciences to a “hold” rating in a research note on Tuesday, July 14th. Wall Street Zen cut Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Finally, Weiss Ratings lowered Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Tiziana Life Sciences currently has a consensus rating of “Reduce”.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.